Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350440 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
A Phase 2 study of Spinocerebellar Ataxia, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT01350440 is a Phase 2 study of Spinocerebellar Ataxia that has completed, run by University of South Florida. The registered enrollment target is 5 participants, below the 215-participant average among 3 other Spinocerebellar Ataxia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01350440, a Phase 2 study of Spinocerebellar Ataxia, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a preliminary study to determine the safety and efficacy of intravenous immune globulin in treating Spinocerebellar Ataxia. The investigators aim to assess changes in clinical measures of disease severity before and after treatment.
Conditions Studied
Interventions
- BIOLOGICAL IVIG
Study Locations (1)
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01350440
The ClinicalTrials.gov registry entry for NCT01350440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 3 other Spinocerebellar Ataxia trials with a reported enrollment target (98% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinocerebellar Ataxia appearing as the primary indexed condition, and to 1 intervention - of which IVIG is the first listed.
NCT01350440 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01350440 about?
NCT01350440 is a clinical study titled "Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia". This is a preliminary study to determine the safety and efficacy of intravenous immune globulin in treating Spinocerebellar Ataxia. The investigators aim to assess changes in clinical measures of disease severity before and after treatment.
What is the current status of trial NCT01350440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-08. Estimated completion is 2013-07.
What conditions does trial NCT01350440 study?
This clinical trial studies the following conditions: Spinocerebellar Ataxia.
What interventions are being tested in trial NCT01350440?
The interventions under investigation include: IVIG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01350440?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01350440 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinocerebellar Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.